A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
A phase 2 trial of KC1036 in ewing sarcoma, run by Beijing Konruns Pharmaceutical Co., Ltd., now recruiting.
Overview
A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma is a phase 2 interventional study registered as NCT06564272 by Beijing Konruns Pharmaceutical Co., Ltd., with 30 participants planned, started 2024-09-27 and due to reach its primary completion in 2027-04-01. Interventions recorded: KC1036. Conditions listed: Ewing Sarcoma. No results are recorded here; the registry entry is the source.
Setting
A Phase II Study to Evaluate the Safety and Efficacy of KC1036 in Adolescents Aged 12 and Above With Advanced Ewing Sarcoma
Phase
Phase 2
Sponsor
Beijing Konruns Pharmaceutical Co., Ltd.
Registry
Enrolled
30
Similar pages
not linked directly; found by shared links- TrialA Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Shares Beijing Konruns Pharmaceutical, KC1036.
- TrialA Study of KC1036 in Patients with Advanced Thymic Tumors
Shares Beijing Konruns Pharmaceutical, KC1036.
- TrialKC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
Shares Beijing Konruns Pharmaceutical, KC1036.